Search results
Author(s):
Jeffrey W Moses
Added:
1 year ago
CRT 25 - Safety and effectiveness outcomes of the Agent drug-coated balloon (DCB) for the treatment of in-stent restenosis show a major reduction in target lesion failure, including cardiac death, myocardial infarction and target lesion revascularization, compared to balloon angioplasty. The Agent DCB also caused a significant reduction in all target lesion events in comparison with the control…
View more
Author(s):
Francesco Pelliccia
Added:
1 year ago
SCAI 2025 - Insights from antiplatelet therapy after transcatheter aortic valve replacement (TAVR) show patients who received single antiplatelet treatment had significantly lower rates of overall six-month mortality, CV death and non-CV death compared to those treated with double antiplatelet treatment.Dr Francesco Pelliccia (Sapienza University of Rome, Rome, IT) joins us to discuss insights…
View more
Prof. Johanne Silvain
Job title: Prof. Johanne Silvain is professor of medicine at the Pierre and Marie Curie University in Paris, France.
Author
PFO Closure: BCIS Position Statement
Author(s):
Mark Turner
,
Suneil Aggarwal
,
Michael J Mullen
,
et al
Added:
1 year ago
Expert Opinion
Added:
1 month ago
Source:
Interventional Cardiology
Mirjam Boros, Radcliffe CardiologyDe-escalation of dual antiplatelet therapy (DAPT) is a strategy used to improve outcomes after percutaneous coronary intervention (PCI).¹˒² However, the impact of patient sex on the safety and efficacy of these strategies has been unclear. A new network meta-analysis published in the European Heart Journal has investigated these potential differences…
View more
Individualising Antithrombotic Strategies for ACS and CCS
Author(s):
Robert F Storey
Added:
2 years ago
Review Article
Author(s):
Ling Tao
Added:
2 years ago
EuroPCR 2024 — Investigator, Dr Ling Tao joins us to discuss the findings from the CAGEFREE II trial.Compared to drug-eluting stents, drug-coated balloons are associated with faster vessel healing and reduced thrombotic burden, therefore patients treated with DCBs require a less intensive antiplatelet therapy. CAGEFREE II investigated the effectiveness and safety of a tailored one-month DAPT…
View more
Author(s):
Joo-Yong Hahn
Added:
1 year ago
ACC 25 - SMART-CHOICE 3 Trial finds clopidogrel monotherapy to be the optimal anti-thrombotic strategy in high risk patients with contemporary drug-eluting stents.Dr Joo-Yong Hahn (Samsung Medical Center, Seoul, KR) joins us onsite at ACC Conference 2025 to discuss the findings from the SMART-CHOICE 3 study (NCT04418479). The study aims to evaluate the efficacy and safety of clopidogrel…
View more
Author(s):
Josep Rodés-Cabau
Added:
7 months ago
TCT 2025 - Short-term anticoagulation reduced adverse events following left atrial appendage closure (LAAC) compared to dual antiplatelet therapy (DAPT).Dr Josep Rodés-Cabau (Quebec Heart and Lung Institute, Quebec, CA) joins us at TCT 2025 to discuss findings from ANDES trial (NCT03568890) investigating the safety and efficacy of short-term anticoagulation versus DAPT for preventing device…
View more
Author(s):
Hyo-Soo Kim
Added:
1 year ago
ACC 25 - Findings from a stratified study investigating coronary stenting and bleeding risk suggest 3 months are the optimal duration of DAPT after PCI.Dr Hyo-Soo Kim (Seoul National University Hospital, KR) sits down to discuss the first randomized study stratifying patients receiving percutaneous coronary intervention with drug eluting stents according to bleeding risk based on the ARC HBR…
View more